Clostridioides difficile Treatment Selection

Test and treat patients with clinically compatible diarrheal illness rather than a positive molecular result alone. CDI requires compatible manifestations plus stool evidence of a toxigenic strain and toxin activity; NAAT detects toxin genes, whereas toxin enzyme immunoassay (EIA) detects stool toxin. Multistep algorithms using GDH and toxin EIA, arbitrated by NAAT, improve interpretation over a standalone assay.BMJ+2BMJDiscordant Clostridioides difficile diagnostic assay and treatment ...BMJDiscordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland | BMJ Openpublications aapClostridioides difficile Infection in Children: Recent Updates on ...

A NAAT-positive or GDH-positive/toxin-EIA-negative result is indeterminate for treatment selection: it may reflect low-level toxin below EIA detection in true CDI or asymptomatic toxigenic carriage. A third-stage NAAT, GDH, or toxigenic culture can address an apparent false-positive screening result but does not distinguish carriage from active CDI; reassess stool frequency, competing causes of diarrhea, systemic findings, and trajectory before prescribing CDI-directed antibiotics.BMJBMJDiscordant Clostridioides difficile diagnostic assay and treatment practice: a cross-sectional study in a tertiary care hospital, Geneva, Switzerland | BMJ Open

Classify nonsevere disease using WBC no greater than 15,000 cells/mL and serum creatinine below 1.5 mg/dL. Fulminant CDI is defined by hypotension or shock, ileus, or megacolon and requires immediate high-dose vancomycin-based therapy rather than the usual fidaxomicin-versus-vancomycin selection pathway.BMJ+1BMJClostridioides difficile-associated disease - Treatment algorithm | BMJ Best PracticeIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

For an initial nonfulminant episode, select oral fidaxomicin when available and affordable because IDSA/SHEA conditionally prefers it over vancomycin based on improved sustained clinical response. The advantage is reduced recurrence, not a demonstrated difference in initial cure, mortality, or adverse events; therefore oral vancomycin is an appropriate alternative when access, coverage, discharge logistics, or formulary restrictions preclude fidaxomicin.IDSA+1IDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in AdultsPubMedNavigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC

Use a 10-day course of fidaxomicin or oral vancomycin for initial nonfulminant CDI. Metronidazole is no longer preferred and should be reserved for settings in which fidaxomicin and vancomycin are unavailable.BMJ+2BMJClostridioides difficile-associated disease - Treatment algorithm | BMJ Best PracticeNatureExperimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature CommunicationsIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

Give particular weight to sustained response when recurrence would carry disproportionate consequences, such as a prior CDI history or a patient in whom further microbiome disruption would be especially consequential. Recurrence after an initial episode occurs in up to 25% of patients within 2 to 8 weeks after antibiotic treatment, and recurrence probability rises after each episode.NatureNatureExperimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature Communications

For fulminant CDI, administer vancomycin 500 mg orally or by nasogastric tube four times daily and add intravenous metronidazole 500 mg every 8 hours. IDSA/SHEA continues to recommend vancomycin rather than fidaxomicin in this setting because fulminant disease was excluded from the trials supporting fidaxomicin.IDSA+1IDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in AdultsPubMedManagement of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

If ileus is present, add rectal vancomycin retention enemas every 6 hours because oral or nasogastric delivery may not reliably reach the colon. Manage fulminant disease in a setting capable of intensive monitoring, and obtain early surgical consultation while medical therapy is initiated because fulminant CDI can progress rapidly.ScienceDirect+1ScienceDirectMy Treatment Approach to Clostridioides difficile InfectionPubMedManagement of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

The immediate objective is not recurrence optimization but restoration of perfusion, colonic drug exposure, and control of systemic toxicity. Reassess hemodynamics, abdominal examination, ileus, and evidence of megacolon serially; persistent deterioration despite appropriate combination therapy should trigger urgent escalation rather than substitution with routine nonfulminant regimens.IDSA+1IDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in AdultsPubMedManagement of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

For a first recurrence, prefer fidaxomicin over a standard vancomycin course when feasible. Vancomycin remains effective for initial clinical cure, and an extended tapered-and-pulsed vancomycin regimen is an accepted alternative, especially where fidaxomicin access is constrained or in patients with multiple recurrences.IDSA+1IDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in AdultsPubMedNavigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC

Consider a single intravenous dose of bezlotoxumab as adjunctive recurrence prevention in patients with a CDI recurrence within the prior 6 months. It is a monoclonal antibody against toxin B and is used with—not instead of—an active CDI antibiotic regimen; select it for patients in whom preventing another episode has high clinical value.ScienceDirect+1ScienceDirectMy Treatment Approach to Clostridioides difficile InfectionPubMedManagement of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

For second or subsequent recurrence, avoid cycling indefinitely through standard 10-day antibiotic courses. Options include fidaxomicin, tapered-and-pulsed vancomycin, or vancomycin followed by rifaximin 400 mg orally every 8 hours for 20 days; after appropriate antibiotic treatment for at least two recurrences, proceed to fecal microbiota transplantation or another microbiota-based recurrence-prevention strategy.PubMedPubMedManagement of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

At treatment initiation, discontinue the inciting antimicrobial when possible and review ongoing acid-suppressive therapy because antibiotic stewardship and discontinuation of chronic acid suppression are identified prevention and management measures. When the non-CDI antibacterial cannot be stopped, document the indication and narrow or shorten it whenever clinically safe.BMJ+1BMJClostridioides difficile-associated disease - Management Approach | BMJ Best PracticeScienceDirectReview Management of Clostridioides difficile Infection: Diagnosis ...

Assess clinical response during therapy by stool frequency, systemic status, volume needs, abdominal findings, WBC, and creatinine rather than using repeat stool assays as a surrogate for cure. For initial and recurrent nonfulminant disease, the key comparative endpoint favoring fidaxomicin is sustained response at 4 weeks for initial CDI and at 30 days in recurrent CDI; cure, mortality, and adverse-event rates were comparable with vancomycin in pooled analyses.PubMedPubMedNavigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - PMC

A return of compatible diarrhea 2 to 8 weeks after therapy should prompt reassessment for recurrence, because this is the usual reported recurrence window after an initial treated episode. Repeat multistep testing only in a patient with recurrent symptoms compatible with CDI; then select therapy according to whether this is the first versus subsequent recurrence and whether the patient has progressed to fulminant illness.Nature+1NatureExperimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family | Nature Communicationspublications aapClostridioides difficile Infection in Children: Recent Updates on ...